Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMA5B1S)

Drug Name
KRN-330 Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMA5B1S

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cell surface A33 antigen (GPA33) TT96HUR GPA33_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cell surface A33 antigen (GPA33) DTT GPA33 4.42 10.076 3.916 9.844
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cell surface A33 antigen (GPA33) DTT GPA33 1.62E-10 -1.19 -5.77
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.